President Donald Trump told workers at a Mack Trucks plant in Pennsylvania on Tuesday that significantly reduced prices for popular weight-loss medications could improve Americans’ health, reduce healthcare costs, and help Republicans in the 2026 midterm elections.
The president announced Medicare beneficiaries will gain access to GLP-1 medications starting July 1 at a cost of as low as $50 per month under a new federal program. He noted seniors who previously faced monthly expenses ranging from $1,200 to $1,400 for these drugs could see dramatic reductions in costs.
According to the White House, agreements with major pharmaceutical manufacturers have already lowered prices for several GLP-1 medications through the administration’s TrumpRx initiative. The average monthly cost for Ozempic has decreased from approximately $1,028 to about $350, while injectable Wegovy dropped from $1,349 to as little as $199 per month depending on dosage.
Trump argued expanding access to these medications would improve public health by addressing obesity and related conditions such as diabetes and heart disease. Advocates of broader GLP-1 access have contended that lower obesity rates could eventually lead to reduced healthcare spending and increased workforce participation through improved health outcomes.
The president also linked the drug pricing initiative to his broader affordability agenda, stating lower prescription costs combined with lower energy prices and Republican tax policies would leave more money in American households. Trump has increasingly emphasized affordability as he prepares for next year’s congressional elections, with the White House identifying healthcare, energy costs, and consumer expenses as critical economic issues for voters.
The Pennsylvania event represented one of Trump’s most direct efforts to position lower healthcare costs as both an economic achievement and a political asset as Republicans seek to maintain their majority in Congress during the 2026 midterms.
